Revvity (NYSE:RVTY) Updates FY 2026 Earnings Guidance

Revvity (NYSE:RVTY) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 5.200-5.300 for the period, compared to the consensus EPS estimate of 5.400. The company issued revenue guidance of $2.8 billion-$2.8 billion, compared to the consensus revenue estimate of $3.0 billion.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on RVTY. Weiss Ratings downgraded shares of Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Stifel Nicolaus set a $100.00 price objective on shares of Revvity in a report on Wednesday. TD Cowen restated a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Robert W. Baird set a $117.00 target price on shares of Revvity in a report on Wednesday. Finally, Barclays restated an “equal weight” rating and issued a $95.00 target price (down from $118.00) on shares of Revvity in a report on Tuesday, April 14th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $107.73.

Revvity Price Performance

Shares of Revvity stock traded up $5.04 during trading hours on Wednesday, hitting $97.34. The company’s stock had a trading volume of 325,767 shares, compared to its average volume of 1,260,838. The business has a 50 day moving average price of $90.23 and a two-hundred day moving average price of $96.82. Revvity has a 12-month low of $81.22 and a 12-month high of $118.30. The company has a market cap of $10.88 billion, a PE ratio of 46.82, a PEG ratio of 1.84 and a beta of 1.05. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.07 million. During the same period in the prior year, the firm earned $1.01 EPS. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Analysts expect that Revvity will post 5.39 earnings per share for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Friday, July 17th. Revvity’s dividend payout ratio is 13.46%.

Key Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 beat on both top and bottom line: Revvity reported $1.06 GAAP EPS vs. $1.02 consensus and revenue of $711.1M vs. ~$704M expected, with revenue +7% YoY — a clear near?term catalyst that drove initial upside. Article Title
• Positive Sentiment: Underlying organic growth and execution: management cited ~3% organic growth and portfolio execution that helped offset margin pressures, supporting expectations for stable life?sciences performance. Article Title
• Neutral Sentiment: Call materials and transcript available — investors can review management’s commentary and slides for color on margins, China exposure and product demand (useful for assessing whether the beat is durable). Article Title
• Neutral Sentiment: Portfolio action: management flagged plans around the China ImmunoDx business (divestiture plans mentioned), which could reshape margins and growth but adds near?term uncertainty until completed. Article Title
• Negative Sentiment: Downward FY?2026 guidance: Revvity set EPS guidance of $5.20–$5.30 (below the ~$5.40 consensus) and issued revenue guidance near $2.8B vs. ~ $3.0B expected — management’s guide trimmed upside and pressured the stock after the initial beat. Article Title
• Negative Sentiment: Analyst reaction: at least one firm cut its price target (Robert W. Baird to $125) and brokers show an average “Hold” recommendation, which can limit near?term upside until guidance concerns are resolved. Article Title

Institutional Investors Weigh In On Revvity

Hedge funds and other institutional investors have recently bought and sold shares of the company. CYBER HORNET ETFs LLC purchased a new stake in Revvity during the second quarter valued at approximately $32,000. MUFG Securities EMEA plc purchased a new position in shares of Revvity during the second quarter worth $34,000. Headlands Technologies LLC purchased a new position in shares of Revvity during the second quarter worth $49,000. Los Angeles Capital Management LLC purchased a new position in shares of Revvity during the fourth quarter worth $51,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Revvity during the fourth quarter worth $72,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.